Deuremidevir

Deuremidevir
Clinical data
Trade names	民得维
Routes of; administration	oral
Legal status
Legal status	US: Investigational drug; CN: conditially Rx;
Identifiers
	IUPAC name [(2R,3R,4R,5R)-5-(4-amino-5-deuteriopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-bis(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate;
CAS Number	2647442-33-7;
PubChem CID	163358784;
ChemSpider	115285279;
UNII	MF2PS6XPS4;
Chemical and physical data
Formula	C24H30DN5O7
Molar mass	502.546 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [2H]c2cc([C@]1(C#N)O[C@H](COC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H]1OC(=O)C(C)C)n3ncnc(N)c23;
	InChI InChI=InChI=1S/C24H31N5O7/c1-12(2)21(30)33-9-16-18(34-22(31)13(3)4)19(35-23(32)14(5)6)24(10-25,36-16)17-8-7-15-20(26)27-11-28-29(15)17/h7-8,11-14,16,18-19H,9H2,1-6H3,(H2,26,27,28)/t16-,18-,19-,24+/m1/s1/i7D; Key:RVSSLHFYCSUAHY-QXMJNOOVSA-N;

Deuremidevir, also known as VV116, is an nucleoside analogue antiviral drug. It is administrated through oral tablets, which contain the hydrobromide salt of this drug.[1]

Chemically speaking, the drug is a deuterated tri-isobutyrate of GS-441524, the active metabolite of remdesivir. It was first described in an 2020 preprint by a team including members of Wuhan Institute of Virology and Vigonvita.[2] It completed a phase 3 trial in 2022.[3] Junshi, which markets the drug, received conditional approval from China's National Medical Products Administration in January 2023.[4]

References

Zhu, Ke-Wei (8 September 2023). "Deuremidevir and Simnotrelvir–Ritonavir for the Treatment of COVID-19". ACS Pharmacology & Translational Science. 6 (9): 1306–1309. doi:10.1021/acsptsci.3c00134.
Yin W, Luan X, Li Z, Xie Y, Zhou Z, Liu J, Gao M, Wang X, Zhou F, Wang Q, Wang Q (January 2020). "Structural basis for repurpose and design of nucleoside drugs for treating COVID-19". bioRxiv. doi:10.1101/2020.11.01.363812. S2CID 226263471.
Cao, Zhujun; Gao, Weiyi; Bao, Hong; Feng, Haiyan; Mei, Shuya; Chen, Peizhan; Gao, Yueqiu; Cui, Zhilei; Zhang, Qin; Meng, Xianmin; Gui, Honglian; Wang, Weijing; Jiang, Yimei; Song, Zijia; Shi, Yiqing; Sun, Jing; Zhang, Yifei; Xie, Qing; Xu, Yiping; Ning, Guang; Gao, Yuan; Zhao, Ren (28 December 2022). "VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19". New England Journal of Medicine: NEJMoa2208822. doi:10.1056/NEJMoa2208822. PMC 9812289. PMID 36577095.
Devarasetti, Hasini (2023-01-30). "China's NMPA conditionally approves two oral drugs for Covid-19". Pharmaceutical Technology. Retrieved 2023-02-04.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Zhu23-1] Zhu, Ke-Wei (8 September 2023). "Deuremidevir and Simnotrelvir–Ritonavir for the Treatment of COVID-19". ACS Pharmacology & Translational Science. 6 (9): 1306–1309. doi:10.1021/acsptsci.3c00134.

[2] Yin W, Luan X, Li Z, Xie Y, Zhou Z, Liu J, Gao M, Wang X, Zhou F, Wang Q, Wang Q (January 2020). "Structural basis for repurpose and design of nucleoside drugs for treating COVID-19". bioRxiv. doi:10.1101/2020.11.01.363812. S2CID 226263471.

[3] Cao, Zhujun; Gao, Weiyi; Bao, Hong; Feng, Haiyan; Mei, Shuya; Chen, Peizhan; Gao, Yueqiu; Cui, Zhilei; Zhang, Qin; Meng, Xianmin; Gui, Honglian; Wang, Weijing; Jiang, Yimei; Song, Zijia; Shi, Yiqing; Sun, Jing; Zhang, Yifei; Xie, Qing; Xu, Yiping; Ning, Guang; Gao, Yuan; Zhao, Ren (28 December 2022). "VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19". New England Journal of Medicine: NEJMoa2208822. doi:10.1056/NEJMoa2208822. PMC 9812289. PMID 36577095.

[4] Devarasetti, Hasini (2023-01-30). "China's NMPA conditionally approves two oral drugs for Covid-19". Pharmaceutical Technology. Retrieved 2023-02-04.